Marksans Pharma Limited has informed the Exchange regarding a press release dated November 17, 2025, titled "Marksans Pharma Limited's wholly owned subsidiary Relonchem Limited receives Marketing Authorisation for its Products from UK MHRA.".
MARKSANS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Marksans Pharma's wholly owned subsidiary, Relonchem Limited, has received Marketing Authorisation for its products from the UK Medicines and Healthcare products Regulatory Agency (MHRA). This approval allows Relonchem to legally market and sell its products in the United Kingdom market. The company shared this update via a press release dated November 17, 2025. UK MHRA approval is a recognised regulatory standard that also often supports market access in other regulated regions.
This is a positive development for shareholders as it opens a new revenue stream in the UK market and strengthens Marksans Pharma's international growth story. It may boost investor confidence, though the actual financial impact will depend on product demand and commercial rollout in the UK.